- Motley Fool•3 days ago
News that Amgen's Repatha lowers the risk of major cardiovascular events could clear the way for this medicine to achieve billion-dollar blockbuster status.
- Zacks•5 days ago
Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process.
- Barrons.com•6 days ago
Shares of biotechnology giant Regeneron Pharmaceuticals (REGN) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded the stock from a neutral to an overweight, with a $446 price ...
RGO.F : Summary for REGENERON PHARMAC.DL-,001 - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (RGO.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
|Bid||352.26 x 2800|
|Ask||352.66 x 2800|
|Day's Range||347.86 - 348.40|
|52 Week Range||36.00 - 348.40|
|PE Ratio (TTM)||45.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|